Highlights Newsletter 3
This newsletter presents you the best read sessions:
1. Final overall survival data from TROPION-Lung01
2. Improved progression-free survival with aumolertinib maintenance in stage III NSCLC
3. Safety outcomes with osimertinib in the phase III LAURA study
4. Dose adjustments and exposure-response associated with selpercatinib in patients with advanced NSCLC